Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Deferred Revenue (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Current Deferred Revenue data on record, last reported at $2.0 million in Q1 2025.

  • For Q1 2025, Current Deferred Revenue fell 81.88% year-over-year to $2.0 million; the TTM value through Mar 2025 reached $2.0 million, down 81.88%, while the annual FY2022 figure was $13.2 million, 54.13% up from the prior year.
  • Current Deferred Revenue reached $2.0 million in Q1 2025 per PLX's latest filing, down from $12.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $18.1 million in Q2 2021 and bottomed at $2.0 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $11.0 million, with a median of $11.8 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: plummeted 86.54% in 2021, then skyrocketed 360.98% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $8.5 million in 2021, then soared by 54.13% to $13.2 million in 2022, then fell by 10.53% to $11.8 million in 2023, then grew by 7.68% to $12.7 million in 2024, then crashed by 84.25% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $2.0 million in Q1 2025, $12.7 million in Q2 2024, and $11.0 million in Q1 2024.